No abstract

No abstract

Background The treatment of advanced cutaneous head and neck cutaneous squamous cell carcinomas (HNcSCC) results in significant morbidity. Recently, immune checkpoint inhibitor treatment has been approved for DNA mismatch repair (MMR) deficient patients in a histology‐agnostic manner. This study aims to evaluate the incidence of MMR deficiency in advanced HNcSCC and its association with clinicopathologic factors. Methods The cohort included 176 consecutive HNcSCC cases treated with curative intent. Immunohistochemistry for MMR proteins (hMLH1, hMSH2, hMSH6, and hPMS2) was performed. Clinicopathological and survival data was collected prospectively. Results The incidence of MMR protein deficiency was 9.1%. There was no association between age, incidence of metachronous malignancies, clinicopathological factors, or survival outcomes. Conclusion A higher incidence of MMR deficiency was observed in this cohort of advanced HNcSCC. The lack of association with young age at onset or increased incidence of metachronous malignancies suggests that MMR deficiency is likely to be sporadic in HNcSCC.

Glomus tumor is an uncommon, benign, soft-tissue lesion in which the cells recapitulate the structure of the normal modified smooth muscle cells of the glomus body. Glomus tumors usually occur in tissues that normally contain glomus bodies; only rarely can they develop in sites where glomus bodies are normally sparse or absent. There are three subtypes of glomus tumor, with glomangiomyoma being the rarest. No more than 10 cases of glomus tumor in female genitalia have previously been reported, involving the vulva, vaginal area, periurethral area and clitoris. A clitoral glomangiomyoma is extremely rare. This is a case report of a glomangiomyoma in the clitoral area. Published reports of glomus tumor in the female external genitalia are reviewed.

Background: Osteoarthritis (OA) is a common chronic articular degenerative disease marked by articular cartilage degradation, synovial inflammation/immunity, and subchondral bone lesion, among other symptoms. The disease affects 2-6% of the global population, and its prevalence increases with age, reaching 40% in people over the age of 70. Recently, there has been a surge of interest in using nutraceuticals to treat or prevent OA. Celery seed extract & Shallaki extracts (Boswellia serrata) effectively prevent cardiovascular disease, urinary tract infection, gout, and improve blood pressure. Experimental results indicate that both these extracts have anti-inflammatory properties. Aim: The current real-world evidence study was conducted to investigate the effectiveness of Celeract Advance Tablet in OA patients. Methods: A total of 1236 patients were enrolled in the study. All patients received Celeract Advance Tablet for 90 days. Clinical assessment of symptoms included palpation tiredness, mobility limitation, joint crepitus, swelling and redness. Osteoarthritis symptoms were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Total European Quality of Life-5 Dimensions and visual analogue scale (VAS). Results: After 90 days treatment with Celeract Advance Tablet, WOMAC score reduced significantly from 62.64 + 20.47 to 17.22 + 17.59 (p< 0.05). For Total European Quality of Life-5 Dimensions (EQ-5D) score significantly improved from 38.76 + 8.10 to 69.13 + 8.60 (p< 0.05). From the baseline, 78.35% improvement in EQ-5D was observed in patients treated for three months. After 90 days, VAS score for pain significantly reduced from 8.07 + 5.38 to 1.78 + 4.46 (P< 0.05) after 90 days in OA patients. No major adverse reactions were reported. Conclusion:The current study revealed that the Celeract Advance tablet effectively improves joint pain, stiffness, physical function and quality of life in OA patients.